please can you make a symposium presentation of etiopathogenesis , clinical feature and complication of hypertensive disorder of pregnancy with standard research article with proper referencing
Reading File
Reading File
Reading File
Finding Sources
Searching PubMed
"hypertensive disorders of pregnancy" AND "preeclampsia" AND etiopathogenesis
Finding Sources
Searching PubMed
"preeclampsia" AND pathogenesis AND placenta
Searching PubMed
"hypertensive disorders of pregnancy" AND clinical features complications management
Reading File
Reading Article
Reading Article
Finding Sources
Reading Article
Searching PubMed
"preeclampsia" AND HELLP syndrome complications eclampsia
Finding Sources
Reading Article
Reading Article
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Running Command
Writing File
Running Command
Running Command
Your symposium presentation is ready!
HDP Symposium Presentation
Presentation · PPTX
What's Inside (26 Slides)
The presentation uses a professional deep navy / teal / gold colour scheme, with dedicated section dividers, two-column comparison slides, and a full reference table at the end.
Slide Structure
| # | Slide | Key Content |
|---|---|---|
| 1 | Title Slide | Full title, subtitle, date, guideline basis |
| 2 | Outline | 12-section roadmap |
| 3 | Global Burden | 5–10% prevalence, 16% maternal deaths in developed countries, long-term outcomes |
| 4–5 | Classification | Section divider + full comparison table: Gestational HTN, PE, Eclampsia, Chronic HTN, Superimposed PE, HELLP |
| 6–10 | Etiopathogenesis | Section divider, Two-Stage Model, Stage 1 (defective trophoblast invasion), Stage 2 (sFlt-1/sEng/VEGF imbalance), vWF/ADAMTS-13/complement pathways |
| 11–12 | Risk Factors | Section divider + two-column slide: strong vs. moderate/controversial risk factors |
| 13–15 | Clinical Features | Section divider + two detailed content slides (hypertension, proteinuria, neuro, hepatic, renal, pulmonary, cardiovascular) |
| 16–17 | Diagnostic Criteria | Section divider + ACOG 2023 diagnostic table |
| 18–20 | Complications | Section divider + maternal complications + HELLP syndrome deep-dive |
| 21 | Fetal/Neonatal | FGR, preterm birth, abruption, perinatal death, long-term offspring risks |
| 22 | Long-term Sequelae | CVD risk, chronic HTN, ESRD, cardiac structural changes, PPCM |
| 23 | Prevention & Management | Aspirin, calcium, antihypertensives, MgSO4, delivery timing |
| 24–25 | References | 10 PubMed articles + 8 textbooks/guidelines, fully cited |
| 26 | Thank You | Discussion slide |
References Included
PubMed Research Articles:
- Dimitriadis et al., Nat Rev Dis Primers 2023 (PMID 36797292)
- Torres-Torres et al., Int J Mol Sci 2024 (PMID 39062815)
- Ohamadike et al., Obstet Gynecol Surv 2022 (PMID 35395093)
- Petca et al., Medicina 2022 - HELLP (PMID 35208649)
- Gardikioti et al., Int J Mol Sci 2022 - molecular advances (PMID 35409211)
- Melchiorre et al., AJOG 2022 - placenta (PMID 33771361)
- Edwards et al., Hypertension 2025 - cardiac meta-analysis (PMID 40365671)
- Huang et al., Curr Cardiol Rev 2025 - PPCM (PMID 39949098)
- Beardmore-Gray et al., Cochrane 2026 - delivery timing (PMID 42161381)
Textbooks: Creasy & Resnik MFM 9e, Goldman-Cecil Medicine, Brenner & Rector's Kidney 11e, Sleisenger & Fordtran GI Disease, plus ACOG, ISSHP, and WHO guidelines.
Find the latest ACOG 2026 updates on PE management and expectant delivery
Searching PubMed
"preeclampsia" AND "ACOG" AND management
Searching PubMed
"preeclampsia" AND "expectant management" AND delivery
Searching the Web
ACOG 2026 preeclampsia management guidelines update
Reading Article
Reading Article
Searching PubMed
"preeclampsia" AND antihypertensive treatment AND 2025
Searching the Web
ACOG practice bulletin preeclampsia 2025 2026 update gestational hypertension delivery timing
Reading Article
Reading Article
Reading Article
Reading Web Page
ACOG preeclampsia management delivery timing 2025 2026 update
Reading Article
Reading Article
Searching the Web
AHA ACC 2025 hypertension guidelines pregnancy preeclampsia recommendations treatment threshold
I now have comprehensive, current data. Here is the full synthesis:
ACOG & Current Evidence on PE Management: Latest Updates (2025–2026)
Important upfront note: As of May 2026, there is no new standalone ACOG Practice Bulletin specifically on preeclampsia published in 2026. The governing document remains ACOG Practice Bulletin No. 222 (Gestational Hypertension and Preeclampsia, 2020/2023 reaffirmation). However, several landmark 2025–2026 studies, a major 2025 AHA guideline update, and a fresh Cochrane review (May 2026) have meaningfully advanced or refined current management.
1. Delivery Timing: The Biggest 2026 Update
Cochrane Review — Beardmore-Gray A et al., May 2026 — the most important new evidence:
- 6 RCTs, 3,491 women with HDP from 34 weeks onwards (including pure PE, mixed HDP, and chronic HTN cohorts)
- Key finding: Planned early birth significantly reduces maternal mortality and morbidity vs expectant management
- RR 0.54 (95% CI 0.37–0.77), high-certainty evidence
- No increased risk of caesarean section with planned early birth (RR 0.94, 95% CI 0.83–1.06)
- Neonatal unit admission was higher with planned early birth — this is the key trade-off
- Clinical takeaway: For women with HDP from 34 weeks, the maternal benefit of planned early birth is now supported by high-certainty evidence, without increasing CS rates. Neonatal unit admission risk must be weighed in counselling, but the maternal benefit is clear.
RCT on Mild Chronic Hypertension (Metz TD et al., Obstet Gynecol 2024 [PMID 39013178]):
- 1,417 participants with mild chronic HTN; delivery ≥39 weeks is favoured
- Planned delivery at 37–38 weeks associated with neonatal RDS (aOR 2.70) and neonatal hypoglycaemia (aOR 1.97–1.82)
- No maternal benefit from early-term delivery vs expectant management
- Takeaway: For mild chronic HTN without superimposed PE, optimise delivery at 39 weeks
2. Antihypertensive Treatment: New Network Meta-Analysis 2025
[Hup RJ et al., Am J Obstet Gynecol 2025 [PMID 40216176]] — Oral antihypertensive network meta-analysis (23 RCTs, 3,989 women):
| Drug | vs Placebo | vs Each Other |
|---|---|---|
| Labetalol | Significant reduction in severe HTN (RR 0.20) | Favoured over nifedipine for reducing PE (RR 0.50) and preterm birth (RR 0.68) |
| Methyldopa | Significant reduction in severe HTN (RR 0.44) | No significant difference vs labetalol on primary outcome |
| Nifedipine | Active; widely used | Slightly less favourable than labetalol on PE/preterm |
- Modest signal favouring labetalol over nifedipine for preventing PE development and preterm birth
- Evidence quality is low-to-moderate overall — ACOG still lists labetalol and nifedipine as co-first-line agents
- Nifedipine GITS dosing RCT (Kiefer MK et al., Hypertension 2025 [PMID 40396237]): In severe PE, nifedipine GITS 30 mg BID reduced the need for emergent antihypertensive rescue vs 60 mg daily — BID dosing now preferred in severe PE
3. ADA 2026 / AHA 2025 Alignment on BP Threshold
- The 2026 ADA Standards of Care have revised their BP treatment threshold in pregnancy to ≥140/90 mmHg — aligning with ACOG's threshold
- The 2025 AHA/ACC Hypertension Guidelines (August 2025) updated their guidance on pregnancy-related hypertension, emphasising early treatment to reduce cardiovascular risk
- Practical implication: There is now cross-guideline consensus — initiate antihypertensives at ≥140/90 mmHg in pregnancy (not the old non-obstetric threshold of ≥160/100)
4. Postpartum Management: Emerging Evidence
[Marques RMCP et al., Pregnancy Hypertens 2025 [PMID 39884047]] — RCT on postpartum HTN management:
- Provides evidence for structured antihypertensive treatment in the early postpartum period
- Supports continued BP monitoring and treatment after delivery
[Cursino T et al., Am J Obstet Gynecol MFM 2025 [PMID 39870324]] — Postpartum furosemide RCT:
- Postpartum furosemide in PE patients: evaluated for accelerating BP and fluid recovery
- Supports selective use of loop diuretics in fluid-overloaded postpartum PE patients
[Countouris M et al., Circulation 2025 [PMID 39960983]] — Major review in Circulation:
- Postpartum maternal health clinics and home BP monitoring programmes shown to improve BP ascertainment and lower BP in months after delivery
- Home BP monitoring is now an evidence-backed, recommended strategy
- Highlights that guidelines differ internationally on optimal BP range and treatment thresholds peripartum — more RCT evidence needed
5. Perioperative / Anaesthetic Management Update
[Dennis AT et al., Anesthesiology 2025 [PMID 39807917]] — Comprehensive PE perioperative review:
- Individualized fluid administration to avoid pulmonary oedema
- Safe neuraxial (preferred) vs general anaesthesia for CS
- Post-CS monitoring for myocardial injury now recommended
- Long-term cardiometabolic follow-up after PE delivery is now explicitly advised
- Postoperative mental health deterioration is newly recognised
6. Practice-Changing Trials — 2026 Synthesis
[Ibirogba ER, Grasch J, Costantine MM. Semin Perinatol 2026 [PMID 41453814]] — "Preeclampsia trials that changed practice":
Key landmark trials summarised:
- CHAP trial — Treatment of mild chronic HTN reduces risk of superimposed PE and complications (target BP <140/90)
- Aspirin trials (ASPRE) — Low-dose aspirin <16 weeks reduces preterm PE by ~60%
- Magpie Trial — MgSO4 superior to diazepam/phenytoin for seizure prophylaxis
- HYPITAT — Planned early birth at 37 weeks in mild PE reduces maternal complications without increasing CS
- Emerging: Statins (pravastatin) — Phase II data promising; Phase III trials ongoing as of 2026
Summary: What Has and Hasn't Changed from ACOG PB 222
| Domain | ACOG PB 222 (2020/2023) | 2025–2026 Updates |
|---|---|---|
| BP threshold | ≥140/90 to initiate Rx | Confirmed; ADA 2026 now aligned |
| Antihypertensives | Labetalol, nifedipine, hydralazine (equal) | New network meta-analysis gives modest edge to labetalol; nifedipine BID preferred in severe PE |
| MgSO4 | Standard for seizure prophylaxis | Unchanged; reaffirmed as gold standard |
| Delivery timing (PE ≥37 wks) | Deliver at 37 wks | Cochrane 2026: planned birth reduces maternal morbidity (high-certainty); neonatal NICU admission risk counselled |
| Delivery timing (34–37 wks) | Expectant if stable | Cochrane 2026 now supports planned early birth — shifted toward earlier delivery |
| Mild chronic HTN delivery | 37–39 wks | RCT: optimise at 39 wks (avoid 37–38 wk delivery) |
| Postpartum care | Basic follow-up | Home BP monitoring, postpartum clinics, loop diuretics, cardiometabolic follow-up |
| Aspirin prevention | 81 mg/day <16 wks | Unchanged |
| Statins | Not recommended | Phase II promising; Phase III ongoing |
Bottom line: No new 2026 ACOG bulletin has been published specifically on preeclampsia as of May 2026. The most significant new evidence is the Cochrane May 2026 review strongly favouring planned early birth over expectant management for HDP from 34 weeks, the antihypertensive network meta-analysis modestly favouring labetalol, and cross-guideline alignment at ≥140/90 mmHg as the treatment threshold. Watch for a potential ACOG bulletin update later in 2026 that may incorporate the Cochrane findings into formal delivery timing recommendations.
This is a shared conversation. Sign in to Orris to start your own chat.